Lunai Bioworks Inc. (NASDAQ: LNAI) announced its subsidiary BioSymetrics entered a multi-year commercial collaboration with a biotechnology partner to develop an AI-enabled platform for chemical threat assessment.

Under the agreement, BioSymetrics will deploy its phenotypic screening and artificial intelligence capabilities to identify and classify neuroactive and neurotoxic compounds. The collaboration represents an expansion of Lunai Bioworks' presence in defense and national security applications.

BioSymetrics will combine zebrafish-based phenotypic screening with AI-driven mechanism-of-action prediction to evaluate compounds of interest. The screening systems can evaluate hundreds to thousands of compounds per week, according to the company.

The collaboration includes experimental screening of central nervous system-active agents, AI-based computational modeling to predict mechanisms of action, and integration of biological and computational datasets. The platform aims to improve identification of neuroactive and toxic compounds.

"This collaboration reflects Lunai Bioworks' commitment to applying cutting-edge AI and phenotypic science to real-world challenges in global security," said David Weinstein, chief executive officer of Lunai Bioworks. "BioSymetrics' platform is uniquely positioned to bridge experimental biology and machine learning, enabling faster and more reliable insights into complex chemical threats."

The project supports Lunai Bioworks' strategy to advance dual-use technologies spanning defense and pharmaceutical applications, including toxicity prediction, drug safety, and neurobiology. The company described the engagement as revenue-generating with additional engagements under discussion.